UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study

Expert review of pharmacoeconomics & outcomes research, 2023-10, Vol.23 (9), p.1057-1066

2023

Link zum Volltext

Verfügbarkeit prüfen

Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program

Expert review of pharmacoeconomics & outcomes research, 2023-12, p.1-15

2023

Link zum Volltext

Verfügbarkeit prüfen

Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population

Expert review of pharmacoeconomics & outcomes research, 2022-06, Vol.22 (4), p.683-690

2022

Link zum Volltext

Verfügbarkeit prüfen

Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain

Expert review of pharmacoeconomics & outcomes research, 2021-03, Vol.21 (2), p.315-320

2021

Link zum Volltext

Verfügbarkeit prüfen

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Expert review of pharmacoeconomics & outcomes research, 2021-07, Vol.21 (4), p.527-540

2021

Link zum Volltext

Verfügbarkeit prüfen

Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies - can alignment be improved?

Expert review of pharmacoeconomics & outcomes research, 2024-02, Vol.24 (2), p.251-265

2024

Link zum Volltext

Verfügbarkeit prüfen

Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective

Expert review of pharmacoeconomics & outcomes research, 2024-02, Vol.24 (2), p.237-250

2024

Link zum Volltext

Verfügbarkeit prüfen

Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment

Expert review of pharmacoeconomics & outcomes research, 2024-04, Vol.24 (4), p.509

2024

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer

Expert review of pharmacoeconomics & outcomes research, 2024-04, Vol.24 (4), p.559

2024

Link zum Volltext

Verfügbarkeit prüfen

The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature

Expert review of pharmacoeconomics & outcomes research, 2021-07, Vol.21 (4), p.553-558

2021

Link zum Volltext

Verfügbarkeit prüfen

How to create value with constrained budgets in oncological care? A narrative review

Expert review of pharmacoeconomics & outcomes research, 2023-10, Vol.23 (9), p.989-999

2023

Link zum Volltext

Verfügbarkeit prüfen

Willingness to pay for cancer prevention, screening, diagnosis, and treatment: a systematic review

Expert review of pharmacoeconomics & outcomes research, 2023-03, Vol.23 (3), p.281-295

2023

Link zum Volltext

Verfügbarkeit prüfen

How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015-2021

Expert review of pharmacoeconomics & outcomes research, 2023-01, Vol.23 (1), p.99-109

2023

Link zum Volltext

Verfügbarkeit prüfen

A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis

Expert review of pharmacoeconomics & outcomes research, 2023-02, Vol.23 (2), p.251-265

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review

Expert review of pharmacoeconomics & outcomes research, 2022-06, Vol.22 (4), p.555-574

2022

Link zum Volltext

Verfügbarkeit prüfen

Adoption of new therapies in the treatment of Hepatitis: a verification of the accuracy of budget impact analysis to guide investment decisions

Expert review of pharmacoeconomics & outcomes research, 2022-08, Vol.22 (6), p.927-939

2022

Link zum Volltext

Verfügbarkeit prüfen

The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review

Expert review of pharmacoeconomics & outcomes research, 2021-03, Vol.21 (2), p.221-233

2021

Link zum Volltext

Verfügbarkeit prüfen

Budget impact analysis of medicines: estimated values versus real-world evidence and the implications

Expert review of pharmacoeconomics & outcomes research, 2022-02, Vol.22 (2), p.271-281

2022

Link zum Volltext

Verfügbarkeit prüfen

Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years

Expert review of pharmacoeconomics & outcomes research, 2021-05, Vol.21 (3), p.479-488

2021

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china

Expert review of pharmacoeconomics & outcomes research, 2021-07, Vol.21 (4), p.691-697

2021

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients

Expert review of pharmacoeconomics & outcomes research, 2021-03, Vol.21 (2), p.265-275

2021

Link zum Volltext

Verfügbarkeit prüfen

The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998-2017

Expert review of pharmacoeconomics & outcomes research, 2021-05, Vol.21 (3), p.476-477

Lichtenberg, Frank R.

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China

Expert review of pharmacoeconomics & outcomes research, 2020-05, Vol.20 (3), p.313-320

2020

Link zum Volltext

Verfügbarkeit prüfen

Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study

Expert review of pharmacoeconomics & outcomes research, 2019-04, Vol.19 (2), p.223-230

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis Online

ThemaHealth Care Sciences & Services

ThemaPharmacology & Pharmacy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

13 weitere anzeigen...

Weniger anzeigen...

Kollektion

Taylor & Francis Current Content Access
(24)
Ovid SocietyJournals and Single Titles
(22)
MEDLINE
(16)

Zeitschrift / Serie

Expert Review Of Pharmacoeconomics & Outcomes Research
(24)

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study

Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program

Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population

Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies - can alignment be improved?

Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective

Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment

Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer

The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature

How to create value with constrained budgets in oncological care? A narrative review

Willingness to pay for cancer prevention, screening, diagnosis, and treatment: a systematic review

How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015-2021

A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis

Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review

Adoption of new therapies in the treatment of Hepatitis: a verification of the accuracy of budget impact analysis to guide investment decisions

The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review

Budget impact analysis of medicines: estimated values versus real-world evidence and the implications

Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years

Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china

Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients

The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998-2017

Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China

Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study

Aktive Filter

Suchergebnisse filtern